TY  - JOUR
A1  - Gründahl, Marie
A1  - Wacker, Beate
A1  - Einsele, Hermann
A1  - Heinz, Werner J.
T1  - Invasive fungal diseases in patients with new diagnosed acute lymphoblastic leukaemia
JF  - Mycoses
N2  - Background
Patients with acute leukaemia have a high incidence of fungal infections. This has primarily been shown in acute myeloid leukaemia and is different for acute lymphoblastic leukaemia. Until now no benefit of mould active prophylaxis has been demonstrated in the latter population.

Methods
In this retrospective single‐centre study, we analysed the incidence, clinical relevance, and outcome of invasive fungal diseases (IFD) as well as the impact of antifungal prophylaxis for the first 100 days following the primary diagnosis of acute lymphoblastic leukaemia.

Results
In 58 patients a high rate of proven, probable, and possible fungal infections could be demonstrated with a 3.4%, 8.6%, and 17.2% likelihood, respectively. The incidence might be even higher, as nearly 40% of all patients had no prolonged neutropenia for more than 10 days, excluding those from the European Organization of Research and Treatment of cancer and the Mycoses Study Group criteria for probable invasive fungal disease. The diagnosed fungal diseases had an impact on the duration of hospitalisation, which was 13 days longer for patients with proven/probable IFD compared to patients with no signs of fungal infection. Use of antifungal prophylaxis did not significantly affect the risk of fungal infection.

Conclusion
Patients with acute lymphoblastic leukaemia are at high risk of acquiring an invasive fungal disease. Appropriate criteria to define fungal infections, especially in this population, and strategies to reduce the risk of infection, including antifungal prophylaxis, need to be further evaluated.
KW  - acute lymphoblastic leukaemia
KW  - fungal infection
KW  - galactomannan
KW  - incidence
KW  - mortality
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-217844
VL  - 63
IS  - 10
SP  - 1101
EP  - 1106
ER  - 
TY  - JOUR
A1  - Ullmann, Andrew J.
A1  - Schmidt-Hieber, Martin
A1  - Bertz, Hartmut
A1  - Heinz, Werner J.
A1  - Kiehl, Michael
A1  - Krüger, William
A1  - Mousset, Sabine
A1  - Neuburger, Stefan
A1  - Neumann, Silke
A1  - Penack, Olaf
A1  - Silling, Gerda
A1  - Vehreschild, Jörg Janne
A1  - Einsele, Hermann
A1  - Maschmeyer, Georg
T1  - Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
JF  - Annals of Hematology
N2  - Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.
KW  - Bone-marrow-transplantation
KW  - Pneumocystis-carinii-pneumonia
KW  - Influenzae type B
KW  - Respiratory syncytial virus
KW  - Infections
KW  - invasive fungal infections
KW  - Varicella-Zoster-Virus
KW  - Hepatitis B virus
KW  - Herpes simplex virus
KW  - Human immunodefiency virus
KW  - Low-dose acyclovir
KW  - Viral
KW  - Fungal
KW  - Bacteria
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-187587
VL  - 95
IS  - 9
ER  -